June 11, 2018/by eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg 0 0 eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg eallison2018-06-11 13:28:412018-06-11 13:28:41APX001 is effective against echinocandin and multidrug resistant Candida isolates Scroll to top READ FULL TEXT
Category: News
APX001 is effective against echinocandin and multidrug resistant Candida isolates
June 11, 2018/by eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg 0 0 eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg eallison2018-06-11 13:28:412018-06-11 13:28:41APX001 is effective against echinocandin and multidrug resistant Candida isolates Scroll to top READ FULL TEXT
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 READ FULL TEXT
Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
SAN DIEGO – June 7, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its collaborators will be participating in and presenting at two scientific conferences in the upcoming weeks. Presentations will focus on the company’s lead drug candidate, APX001, which is currently in development for the treatment of invasive...
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology READ FULL TEXT
VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks
VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks The company will also present five posters featuring its lead clinical antibacterial candidate, cefepime/VNRX-5133 Malvern, PA, May 31, 2018 – VenatoRx Pharmaceuticals will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133, at ASM Microbe which is taking place...
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 READ FULL TEXT
VenatoRx Pharmaceuticals to Present at the 2018 UBS Global Healthcare Conference
Malvern, PA — VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018. Dr. Burns will present attendees with an overview of VenatoRx’s pipeline and its unique...
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
WASHINGTON, Jan. 29, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious...
VenatoRx Pharmaceuticals Founders Christopher J. Burns, Ph.D., Luigi Xerri, Ph.D. and Daniel C. Pevear, Ph.D. named EY Entrepreneur Of The Year 2018 Finalists in the Greater Philadelphia Area
VenatoRx Pharmaceuticals Founders Christopher J. Burns, Ph.D., Luigi Xerri, Ph.D. and Daniel C. Pevear, Ph.D. named EY Entrepreneur Of The Year 2018 Finalists in the Greater Philadelphia Area Malvern, PA, April 19, 2018 EY today announced that VenatoRx Pharmaceuticals’ founders Christopher J. Burns, Ph.D., President and CEO, Luigi Xerri, Ph.D., Chief Development Officer, and...